Our recent study demonstrated that patients with pT3-4 upper urinary tract urothelial carcinoma negative for both ERα and progesterone receptor (PR) had a significantly lower risk of cancer-specific mortality, compared with those showing ERα and/or PR positivity [51]. This evidence concerns the gene ESR1 and cancer.